Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
AssigneeEli Lilly and Company
InventorsJulie Kay Bush, Preston Charles Conrad, Merlyn Gerard Flom
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathological conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT.
Claims4
Crystalline 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride hydrate (F-III) having an X-ray diffraction pattern which comprises the following peaks:
- 4.6±0.2, 7.8±0.2, 9.3±0.2, 14.0±0.2, 17.6±0.2, 20.8±0.2, and 24.3±0.2° in 2θ;
- when obtained at 25±2° C. and 35±10% relative humidity from a copper radiation source (CuKα;
- λ=1.54056 Å).
Dependencies are inferred from the claim text.